Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
17hon MSN
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
MarketWatch on MSN10d
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds — and she’s not aloneTori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...
Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.
Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback